{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:47Z","timestamp":1772165627733,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2022KTSCX021"],"award-info":[{"award-number":["2022KTSCX021"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2022KTSCX021"],"award-info":[{"award-number":["2022KTSCX021"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2022KTSCX021"],"award-info":[{"award-number":["2022KTSCX021"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03688-3","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:53:29Z","timestamp":1740380009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PD-1 inhibitor combined with chemotherapy or lenvatinib in advanced gallbladder cancer: a retrospective comparative study"],"prefix":"10.1186","volume":"25","author":[{"given":"Hong-yan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin-wen","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"3688_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3688_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"3688_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/000313481708300721","volume":"83","author":"CG Ethun","year":"2017","unstructured":"Ethun CG, Le N, Lopez-Aguiar AG, et al. Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. Am Surg. 2017;83:679\u201386.","journal-title":"Am Surg"},{"key":"3688_CR4","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol. 2016;27:v28\u201337.","journal-title":"Ann Oncol"},{"key":"3688_CR5","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, et al. Effcacy and safety of pembrolizumab or the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147:2190\u20138.","journal-title":"Int J Cancer"},{"key":"3688_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, et al. RECIST1.1 standard and disease specific adaptations: Perspectives from the RECIST working group. Eur J Cancer. 2016;62:138\u201345.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3688_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S. Using the common terminology criteria for adverse events to evaluate the severity of adverse events of anticancer therapies. Actas Dermosififiliogr. 2021;112(1):90\u20132.","journal-title":"Actas Dermosififiliogr"},{"issue":"12","key":"3688_CR8","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"A Lamarca","year":"2014","unstructured":"Lamarca A, Hubner RA, David Ryder W, et al. Second-line chemotherapy in advanced biliary cancer: a systematic review[J]. Ann Oncol. 2014;25(12):2328\u201338.","journal-title":"Ann Oncol"},{"issue":"3","key":"3688_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4143\/crt.2018.326","volume":"51","author":"J Hyung","year":"2019","unstructured":"Hyung J, Kim B, Yoo C, et al. Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin[J]. Cancer Res Treat. 2019;51(3):901\u20139.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"3688_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","volume":"71","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Chen D, Wang PI, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017;71(3):405\u201314.","journal-title":"Eur Urol"},{"key":"3688_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41:868\u201376.","journal-title":"Cancer Treat Rev"},{"key":"3688_CR12","doi-asserted-by":"publisher","first-page":"e1331807","DOI":"10.1080\/2162402X.2017.1331807","volume":"6","author":"Z Wang","year":"2017","unstructured":"Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6:e1331807.","journal-title":"Oncoimmunology"},{"key":"3688_CR13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.7150\/jca.23290","volume":"9","author":"W Cai","year":"2018","unstructured":"Cai W, Yuan Y, Ge W. EGFR target therapy combined with GEMOX for advanced biliary tract cancers: A meta-analysis based on RCTs. J Cancer. 2018;9:1476\u201385.","journal-title":"J Cancer"},{"key":"3688_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.21873\/invivo.11798","volume":"34","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Frega G, Ricci AD. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis. In Vivo. 2020;34:479\u201388.","journal-title":"In Vivo"},{"key":"3688_CR15","doi-asserted-by":"crossref","unstructured":"Robin Kate Kelley*, Makoto Ueno*, Changhoon Yoo. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet. 2023;401:1853\u201365.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"issue":"8","key":"3688_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a nonrandomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol. 2019;4(8):611\u201321.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3688_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, et al. Whole-Exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872\u20136.","journal-title":"Nat Genet"},{"issue":"10027","key":"3688_CR18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD- L1- positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"3","key":"3688_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud Coffin","year":"2019","unstructured":"Arnaud Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessingimmune check point inhibitors[J]. Int J Cancer. 2019;145(3):639\u201348.","journal-title":"Int J Cancer"},{"issue":"6349","key":"3688_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"4","key":"3688_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene Expression Profile, Programmed Death Ligand 1 Expression and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028[J]. J Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03688-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:53:32Z","timestamp":1740380012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03688-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3688"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03688-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3992736\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board and Ethics Committee of the Southern Medical University Shenzhen Hospital(No.2022KTSCX021). This research was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}